130 related articles for article (PubMed ID: 19301450)
1. Irbesartan for heart failure with preserved ejection fraction.
Schillaci G; Pucci G; Pirro M
N Engl J Med; 2009 Mar; 360(12):1258; author reply 1258-9. PubMed ID: 19301450
[No Abstract] [Full Text] [Related]
2. Irbesartan for heart failure with preserved ejection fraction.
Ghali JK
N Engl J Med; 2009 Mar; 360(12):1257; author reply 1258-9. PubMed ID: 19301448
[No Abstract] [Full Text] [Related]
3. Irbesartan for heart failure with preserved ejection fraction.
Amato JL; Amato JL
N Engl J Med; 2009 Mar; 360(12):1256-7; author reply 1258-9. PubMed ID: 19297582
[No Abstract] [Full Text] [Related]
4. Irbesartan for heart failure with preserved ejection fraction.
Tomoda H
N Engl J Med; 2009 Mar; 360(12):1257-8; author reply 1258-9. PubMed ID: 19301449
[No Abstract] [Full Text] [Related]
5. Irbesartan in patients with heart failure and preserved ejection fraction.
Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C; Ptaszynska A;
N Engl J Med; 2008 Dec; 359(23):2456-67. PubMed ID: 19001508
[TBL] [Abstract][Full Text] [Related]
6. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
[TBL] [Abstract][Full Text] [Related]
7. Irbesartan in patients with atrial fibrillation.
; Yusuf S; Healey JS; Pogue J; Chrolavicius S; Flather M; Hart RG; Hohnloser SH; Joyner CD; Pfeffer MA; Connolly SJ
N Engl J Med; 2011 Mar; 364(10):928-38. PubMed ID: 21388310
[TBL] [Abstract][Full Text] [Related]
8. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy.
Cardiovasc J Afr; 2008; 19(6):337-8, discussion 339. PubMed ID: 19104736
[No Abstract] [Full Text] [Related]
9. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Shah RV; Desai AS; Givertz MM
J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Lam CS; Carson PE; Anand IS; Rector TS; Kuskowski M; Komajda M; McKelvie RS; McMurray JJ; Zile MR; Massie BM; Kitzman DW
Circ Heart Fail; 2012 Sep; 5(5):571-8. PubMed ID: 22887722
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
[TBL] [Abstract][Full Text] [Related]
12. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
[TBL] [Abstract][Full Text] [Related]
13. Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease.
Packer M
Circ Heart Fail; 2011 Sep; 4(5):538-40. PubMed ID: 21934089
[No Abstract] [Full Text] [Related]
14. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
Damman K; Perez AC; Anand IS; Komajda M; McKelvie RS; Zile MR; Massie B; Carson PE; McMurray JJ
J Am Coll Cardiol; 2014 Sep; 64(11):1106-13. PubMed ID: 25212644
[TBL] [Abstract][Full Text] [Related]
15. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
Campbell RT; Jhund PS; Castagno D; Hawkins NM; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2012 Dec; 60(23):2349-56. PubMed ID: 23141494
[TBL] [Abstract][Full Text] [Related]
16. Understanding heart failure with preserved ejection fraction: clinical importance and future outlook.
Miller AB; Piña IL
Congest Heart Fail; 2009; 15(4):186-92. PubMed ID: 19627293
[TBL] [Abstract][Full Text] [Related]
17. [The I-PRESERVE study].
Trimarco B; Rosei EA
G Ital Cardiol (Rome); 2009 Aug; 10(8):495-8. PubMed ID: 19771745
[No Abstract] [Full Text] [Related]
18. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
Carson P; Massie BM; McKelvie R; McMurray J; Komajda M; Zile M; Ptaszynska A; Frangin G;
J Card Fail; 2005 Oct; 11(8):576-85. PubMed ID: 16230259
[TBL] [Abstract][Full Text] [Related]
19. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
Zile MR; Gaasch WH; Anand IS; Haass M; Little WC; Miller AB; Lopez-Sendon J; Teerlink JR; White M; McMurray JJ; Komajda M; McKelvie R; Ptaszynska A; Hetzel SJ; Massie BM; Carson PE;
Circulation; 2010 Mar; 121(12):1393-405. PubMed ID: 20231531
[TBL] [Abstract][Full Text] [Related]
20. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Tschöpe C; Tschöpe R; Unger T
MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
[No Abstract] [Full Text] [Related]
[Next] [New Search]
